Indium (111in) Dtpa Curium Netherlands Bv (Pentetic Acid, Indium (111in) Pentetate)

Indium‑111 pentetate consists of the chelating agent DTPA bound to the gamma‑emitting isotope Indium‑111. After intrathecal injection, the complex mixes with cerebrospinal fluid and travels throughout the CSF spaces. The emitted gamma photons are detected by imaging equipment, producing visual maps of CSF flow and revealing any abnormal leaks or blockages.

The specific dose of Indium (111in) Dtpa is determined by the prescribing physician based on the patient’s age, weight, clinical indication, and imaging protocol. Dosing is individualized and should follow the relevant nuclear medicine guidelines and institutional policies.

Safety data for Indium (111in) Dtpa in pregnancy and lactation are limited. It should be avoided unless the diagnostic benefit outweighs potential risks to the fetus or infant. If use is essential, a risk‑benefit assessment by the treating physician is required, and appropriate precautions should be taken.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Indium (111in) Dtpa offers high‑resolution gamma imaging and a relatively long half‑life, allowing extended imaging windows compared with short‑lived agents like Technetium‑99m DTPA. It provides clearer delineation of CSF pathways but involves higher radiation exposure, so selection depends on clinical needs, availability, and institutional protocols.

The product should be stored at 2‑8 °C in its original container, protected from light, and must not be frozen or shaken. Handling requires radiation safety measures, including shielding, use of lead containers, and adherence to local radiopharmacy regulations to protect personnel and patients.

Indium (111in) Dtpa is administered by a trained healthcare professional via intrathecal injection, typically through a lumbar puncture. The procedure is performed under sterile conditions, and the patient is monitored for immediate adverse reactions before proceeding with imaging.

Serious risks include allergic reactions ranging from rash to anaphylaxis, rare neurotoxic events such as seizures, infection at the injection site (including meningitis), spinal hemorrhage, and radiation‑induced tissue injury. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to DTPA or indium compounds, those with active spinal infections, uncontrolled coagulopathy, or severe pregnancy should avoid the agent unless the diagnostic benefit clearly outweighs the risks. Clinical judgment is required for each individual case.